Subinhibitory Concentrations of Azithromycin Decrease Nontypeable Haemophilus influenzae Biofilm Formation and Diminish Established Biofilms
99
TL;DR: Data show that subinhibitory concentrations of azithromycin have antibiofilm properties, provide mechanistic insights, and supply an additional rationale for the use of azathromycin in chronic biofilm infections involving H. influenzae.
read more
Abstract: Nontypeable Haemophilus influenzae (NTHi) commonly causes otitis media, chronic bronchitis in emphysema, and early airway infections in cystic fibrosis. Long-term, low-dose azithromycin has been shown to improve clinical outcomes in chronic lung diseases, although the mechanism of action remains unclear. The inhibition of bacterial biofilms by azithromycin has been postulated to be one mechanism mediating these effects. We hypothesized that subinhibitory concentrations of azithromycin would affect NTHi biofilm formation. Laboratory strains of NTHi expressing green fluorescent protein and azithromycin-resistant clinical isolates were grown in flow-cell and static-culture biofilm models. Using a range of concentrations of azithromycin and gentamicin, we measured the degree to which these antibiotics inhibited biofilm formation and persistence. Large biofilms formed over 2 to 4 days in a flow cell, displaying complex structures, including towers and channels. Subinhibitory concentrations of azithromycin significantly decreased biomass and maximal thickness in both forming and established NTHi biofilms. In contrast, subinhibitory concentrations of gentamicin had no effect on biofilm formation. Furthermore, established NTHi biofilms became resistant to gentamicin at concentrations far above the MIC. Biofilm formation of highly resistant clinical NTHi isolates (azithromycin MIC of > 64 microg/ml) was similarly decreased at subinhibitory azithromycin concentrations. Clinically obtainable azithromycin concentrations inhibited biofilms in all but the most highly resistant isolates. These data show that subinhibitory concentrations of azithromycin have antibiofilm properties, provide mechanistic insights, and supply an additional rationale for the use of azithromycin in chronic biofilm infections involving H. influenzae.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Microbial interactions in the respiratory tract.
TL;DR: A significantly greater understanding about microbial physiology is required as it relates to the involvement of biofilms in OM, to identify points in the natural course of the disease that are perhaps more amenable to treatment strategies, as well as to identify biofilm-relevant antigenic targets that would be helpful in the rational design of vaccines to prevent OM.
Effect of nitrofurans and NO generators on biofilm formation by Pseudomonas aeruginosa PAO1 and Burkholderia cenocepacia 370.
TL;DR: Antibacterial drugs in the nitrofuran series, as well as the nitric oxide generators sodium nitroprusside and isosorbide mononitrate in concentrations that do not suppress bacterial growth, were shown to increase the capacity of pathogenic bacteria Pseudomonas aeruginosa PAO1 and Burkholderia cenocepacia 370 to form biofilms.
Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline and ceftriaxone on Staphylococcus epidermidis biofilms
Elisabeth Presterl,Stefan Hajdu,Andrea Lassnigg,Alexander M. Hirschl,Johannes Holinka,Wolfgang Graninger +5 more
TL;DR: The use of a combination of AZI plus TGC, FOS, or CRX at high concentrations has little effect on biofilm density but significantly reduces bacterial growth, and a significant reduction of bacterial growth was achieved with high doses of AZi plus T GC or AZIplus CRX.
Modulation of Biofilm Growth by Sub‐Inhibitory Amounts of Antibacterial Substances
Stoyanka Stoitsova,Tsvetelina Paunova-Krasteva,Dayana Borisova +2 more
- 13 Jul 2016
TL;DR: Differences in experimental protocols should be taken into account, as well as the strain‐specific mechanisms of biofilm formation, which are a source of additional risks for both biofilm infection of host tissues and contamination indwelling devices.
References
Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis
George A. O'Toole,Roberto Kolter +1 more
TL;DR: The genetic analyses suggest that biofilm formation can proceed via multiple, convergent signalling pathways, which are regulated by various environmental signals, and that of the 24 sad mutants analysed in this study, only three had defects in genes of known function.
2.6K
Quantification of biofilm structures by the novel computer program COMSTAT.
Arne Heydorn,Alex Toftgaard Nielsen,Morten Hentzer,Claus Sternberg,Michael Givskov,Bjarne Kjær Ersbøll,Søren Molin +6 more
TL;DR: Analysis of biofilms of P. aureofaciens growing on 0.03 mM, 0.1 mM or 0.5 mM citrate minimal media showed that mean biofilm thickness increased with increasing citrate concentration, whereas surface to volume ratio increased with higher citrate concentrations.
2.1K
New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.
TL;DR: The association between an exacerbation and the isolation of a new strain of a bacterial pathogen supports the causative role of bacteria in exacerbations of chronic obstructive pulmonary disease.
1.1K
•Book
Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments : United States, 1996
Schappert Sm
- 01 Jun 1997
TL;DR: Utilization varied by patient age, sex, and race; Persons 75 years and over had the highest rate of ambulatory care visits; and Females had significantly higher rates of visits to physician offices and hospital outpatient departments than males did.
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Lisa Saiman,Bruce C. Marshall,Bruce C. Marshall,Nicole Mayer-Hamblett,Jane L. Burns,Alexandra L. Quittner,Debra A. Cibene,Sarah Coquillette,Ann Yunker Fieberg,Frank J. Accurso,Preston W. Campbell +10 more
TL;DR: Azithromycin treatment was associated with improvement in clinically relevant end points and should be considered for patients with CF who are 6 years or older and chronically infected with P aeruginosa.
994
Related Papers (5)
Luanne Hall-Stoodley,Fen Z. Hu,Fen Z. Hu,Armin Gieseke,Armin Gieseke,Laura Nistico,Duc Nguyen,Jay Hayes,Michael L. Forbes,David P. Greenberg,Bethany Dice,Amy Burrows,P. Ashley Wackym,Paul Stoodley,Paul Stoodley,J. Christopher Post,J. Christopher Post,Garth D. Ehrlich,Garth D. Ehrlich,Joseph E. Kerschner +19 more